CL2008002654A1 - Compuestos derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, bloqueadores de los canales hcn; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cardiopatias isquemicas, insuficiencias cardiacas tanto sistolicas como diastolicas, entre otras. - Google Patents
Compuestos derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, bloqueadores de los canales hcn; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cardiopatias isquemicas, insuficiencias cardiacas tanto sistolicas como diastolicas, entre otras.Info
- Publication number
- CL2008002654A1 CL2008002654A1 CL2008002654A CL2008002654A CL2008002654A1 CL 2008002654 A1 CL2008002654 A1 CL 2008002654A1 CL 2008002654 A CL2008002654 A CL 2008002654A CL 2008002654 A CL2008002654 A CL 2008002654A CL 2008002654 A1 CL2008002654 A1 CL 2008002654A1
- Authority
- CL
- Chile
- Prior art keywords
- hydrogen
- compounds
- pharmaceutical composition
- group
- optionally substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- MZBVNYACSSGXID-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-1-benzazepine Chemical class N1CCCCC2=CC=CC=C21 MZBVNYACSSGXID-UHFFFAOYSA-N 0.000 title 1
- 206010007559 Cardiac failure congestive Diseases 0.000 title 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 title 1
- 208000008253 Systolic Heart Failure Diseases 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 208000031225 myocardial ischemia Diseases 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 15
- 239000001257 hydrogen Substances 0.000 abstract 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 14
- -1 HYDROGEN-10 Chemical class 0.000 abstract 6
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical group [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B55/00—Racemisation; Complete or partial inversion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
EN LA QUE: R1 REPRESENTA UN ÁTOMO DE HIDRÓGENO O UN GRUPO ELEGIDO ENTRE CICLOALQUILO, BENCILO Y ALQUILO OPCIONALMENTE SUSTITUIDO, R2, R3, R4 Y R5 REPRESENTAN CADA UNO UN ÁTOMO DE HIDRÓGENO O UN GRUPO HIDROXI, METILO, -OS02R10, -OCOR10, ALCOXI OPCIONALMENTE SUSTITUIDO, O BIEN R2 Y R3, O R3 Y R4, O R4 Y RS FORMAN JUNTOS UN GRUPO -O-(CH2)Q-O-, -O-CH=CH-0- O -0-CH=CH-, R6, R7, R8 Y R9 REPRESENTAN CADA UNO UN ÁTOMO DE HIDRÓGENO O UN GRUPO ALCOXI, O BIEN R6 Y R7, O R7 Y R8, O R8 Y R9 FORMAN JUNTOS UN GRUPO -O-(CH2)Q-O-,R10 REPRESENTA UN GRUPO ELEGIDO ENTRE ALCOXI C1-C6 LINEAL O RAMIFICADO, NR11R'11 Y ALQUILO OPCIONALMENTE SUSTITUIDO, R11 Y R'11 REPRESENTAN CADA UNO UN ÁTOMO DE HIDRÓGENO O UN GRUPO ALQUILO, O BIEN R11 Y R'11 FORMAN JUNTOS, CON EL ÁTOMO DE NITRÓGENO QUE LES SOPORTA, UN HETEROCICLO NITROGENADO MONO-O BICÍCLICO OPCIONALMENTE SUSTITUIDO, X REPRESENTA O, NH O CH2, M Y P REPRESENTAN CADA UNO O Ó 1, N Y Q REPRESENTAN CADA UNO 1 Ó 2, EN FORMA RACÉMICA O DE ISÓMEROS ÓPTICOS, ASÍ COMO SUS SALES DE ADICIÓN CON UN ÁCIDO FARMACÉUTICAMENTE ACEPTABLE. ADEMÁS REIVINDICA EL PROCESO DE PREPARACIÓN DE DICHOS COMPUESTOS DE FORMULA (1), UNA COMPOSICIÓN FARMACÉUTICA QUE CONTIENE UN<br /> COMPUESTO DE FÓRMULA (1) Y EL USO DE DICHA COMPOSICIÓN FARMACÉUTICA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0706346A FR2920773B1 (fr) | 2007-09-11 | 2007-09-11 | Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2008002654A1 true CL2008002654A1 (es) | 2009-03-20 |
Family
ID=39323822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2008002654A CL2008002654A1 (es) | 2007-09-11 | 2008-09-08 | Compuestos derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, bloqueadores de los canales hcn; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cardiopatias isquemicas, insuficiencias cardiacas tanto sistolicas como diastolicas, entre otras. |
Country Status (44)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2961105B1 (fr) | 2010-06-15 | 2013-02-08 | Servier Lab | Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| FR2984320B1 (fr) * | 2011-12-20 | 2013-11-29 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| FR2984319B1 (fr) * | 2011-12-20 | 2013-12-27 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| FR2988720B1 (fr) * | 2012-03-27 | 2014-03-14 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| TWI654180B (zh) | 2012-06-29 | 2019-03-21 | 美商艾佛艾姆希公司 | 殺真菌之雜環羧醯胺 |
| FR3003859B1 (fr) * | 2013-03-26 | 2015-03-13 | Servier Lab | "procede de synthese de derives de la 7,8-dimethoxy-1,3-dihydro-2h-3-benzazepin-2-one et application a la synthese de l'ivabradine" |
| WO2015009534A2 (en) | 2013-07-16 | 2015-01-22 | Allergan, Inc. | Hcn inhibitors affecting ganglion cell function and visual function |
| FR3020810B1 (fr) * | 2014-05-06 | 2016-05-06 | Servier Lab | Nouveau sel de l'ivabradine et son procede de preparation. |
| RU2730503C2 (ru) | 2015-12-17 | 2020-08-24 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Терапевтическое средство для лечения рака молочной железы |
| FR3046793B1 (fr) * | 2016-01-14 | 2018-01-05 | Les Laboratoires Servier | Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2018196782A1 (en) * | 2017-04-27 | 2018-11-01 | The University Of Hong Kong | Use of hcn inhibitors for treatment of cancer |
| CN112724001B (zh) * | 2019-10-28 | 2022-12-13 | 鲁南制药集团股份有限公司 | 一种伊伐布雷定手性中间体化合物 |
| CN113372273B (zh) * | 2020-03-10 | 2023-05-09 | 鲁南制药集团股份有限公司 | 一种伊伐布雷定中间体化合物iv |
| CN113372274B (zh) * | 2020-03-10 | 2023-03-24 | 鲁南制药集团股份有限公司 | 一种伊伐布雷定的制备方法 |
| KR20240052933A (ko) * | 2021-08-31 | 2024-04-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 모노사이클릭 피리딘 유도체를 제조하기 위한 방법 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3119874A1 (de) * | 1981-05-19 | 1982-12-09 | Dr. Karl Thomae Gmbh, 7950 Biberach | "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel" |
| DE3418270A1 (de) * | 1984-05-17 | 1985-11-21 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue aminotetralinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| GB8707120D0 (en) * | 1987-03-25 | 1987-04-29 | Pfizer Ltd | Antiarrhythmic agents |
| JPH02193971A (ja) * | 1989-01-20 | 1990-07-31 | Yamanouchi Pharmaceut Co Ltd | トリ置換―２，３，４，５―テトラヒドロベンズアゼピン誘導体とその中間体 |
| FR2681862B1 (fr) * | 1991-09-27 | 1993-11-12 | Adir Cie | Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent. |
| JPH09501405A (ja) * | 1993-05-27 | 1997-02-10 | スミスクライン・ビーチャム・ラボラトワール・ファルマソーティク | 抗不整脈用ｎ−置換３−ベンズアゼピンまたはイソキノリン |
| TW527355B (en) * | 1997-07-02 | 2003-04-11 | Bristol Myers Squibb Co | Inhibitors of farnesyl protein transferase |
| US6514964B1 (en) * | 1999-09-27 | 2003-02-04 | Amgen Inc. | Fused cycloheptane and fused azacycloheptane compounds and their methods of use |
| FR2882554B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| FR2894826B1 (fr) | 2005-12-21 | 2010-10-22 | Servier Lab | Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent |
-
2007
- 2007-09-11 FR FR0706346A patent/FR2920773B1/fr not_active Expired - Fee Related
-
2008
- 2008-08-19 PE PE2008001405A patent/PE20090620A1/es active IP Right Grant
- 2008-08-20 CR CR10229A patent/CR10229A/es unknown
- 2008-08-20 SG SG200806160-8A patent/SG151172A1/en unknown
- 2008-08-21 UY UY31305A patent/UY31305A1/es active IP Right Grant
- 2008-08-26 AP AP2008004589A patent/AP2384A/xx active
- 2008-08-27 MY MYPI20083304A patent/MY143079A/en unknown
- 2008-08-28 AU AU2008207585A patent/AU2008207585B2/en not_active Ceased
- 2008-09-01 MX MX2008011164A patent/MX2008011164A/es active IP Right Grant
- 2008-09-02 CA CA2639349A patent/CA2639349C/fr not_active Expired - Fee Related
- 2008-09-02 TW TW097133661A patent/TWI374029B/zh not_active IP Right Cessation
- 2008-09-03 ZA ZA2008/07586A patent/ZA200807586B/en unknown
- 2008-09-04 UA UAA200810902A patent/UA100003C2/ru unknown
- 2008-09-05 JP JP2008227956A patent/JP4932805B2/ja not_active Expired - Fee Related
- 2008-09-08 MA MA31219A patent/MA30315B1/fr unknown
- 2008-09-08 CL CL2008002654A patent/CL2008002654A1/es unknown
- 2008-09-08 HN HN2008001393A patent/HN2008001393A/es unknown
- 2008-09-09 PA PA20088795301A patent/PA8795301A1/es unknown
- 2008-09-09 US US12/283,110 patent/US8076325B2/en not_active Expired - Fee Related
- 2008-09-09 AR ARP080103906A patent/AR068386A1/es active IP Right Grant
- 2008-09-10 KR KR1020080089213A patent/KR101078076B1/ko not_active Expired - Fee Related
- 2008-09-10 NZ NZ571143A patent/NZ571143A/en not_active IP Right Cessation
- 2008-09-10 NI NI200800247A patent/NI200800247A/es unknown
- 2008-09-10 JO JO2008404A patent/JO2652B1/en active
- 2008-09-10 EA EA200801828A patent/EA014756B1/ru unknown
- 2008-09-10 SA SA08290567A patent/SA08290567B1/ar unknown
- 2008-09-10 EC EC2008008731A patent/ECSP088731A/es unknown
- 2008-09-11 DE DE602008000786T patent/DE602008000786D1/de active Active
- 2008-09-11 CO CO08095781A patent/CO6020016A1/es active IP Right Grant
- 2008-09-11 WO PCT/FR2008/001268 patent/WO2009066041A2/fr not_active Ceased
- 2008-09-11 AT AT08290851T patent/ATE460401T1/de active
- 2008-09-11 RS RSP-2010/0245A patent/RS51305B/sr unknown
- 2008-09-11 ME MEP-2010-45A patent/ME00981B/me unknown
- 2008-09-11 DK DK08290851.8T patent/DK2036892T3/da active
- 2008-09-11 EP EP08290851A patent/EP2036892B1/fr active Active
- 2008-09-11 SI SI200830030T patent/SI2036892T1/sl unknown
- 2008-09-11 PL PL08290851T patent/PL2036892T3/pl unknown
- 2008-09-11 CN CN2008102135506A patent/CN101386594B/zh not_active Expired - Fee Related
- 2008-09-11 ES ES08290851T patent/ES2342511T3/es active Active
- 2008-09-11 CU CU20080165A patent/CU23706B7/es active IP Right Grant
- 2008-09-11 BR BRPI0804091A patent/BRPI0804091B8/pt not_active IP Right Cessation
- 2008-09-11 PT PT08290851T patent/PT2036892E/pt unknown
-
2010
- 2010-05-11 HR HR20100259T patent/HRP20100259T1/hr unknown
- 2010-05-17 CY CY20101100438T patent/CY1110034T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2008002654A1 (es) | Compuestos derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, bloqueadores de los canales hcn; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cardiopatias isquemicas, insuficiencias cardiacas tanto sistolicas como diastolicas, entre otras. | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR045955A1 (es) | Compuestos benzoimidazolicos | |
| AR036659A1 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
| PE20060570A1 (es) | Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10 | |
| AR076753A1 (es) | Derivados de carboxamida y urea aromaticas sustituidas como ligandos del receptor de vanilloides. | |
| UY28823A1 (es) | Compuestos de ácido alfa aril o heteroaril metil beta piperidino propanoico como antagonistas del receptor orl1 | |
| AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
| AR062409A1 (es) | Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto | |
| AR058546A1 (es) | Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1 | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| AR075583A1 (es) | Derivados de isoxazol/o-piridina con eslabon etilo o etenilo | |
| PE20141000A1 (es) | Ureas asimetricas y usos medicos de las mismas | |
| PE20140968A1 (es) | Derivados de benzamida sustituida | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR046085A1 (es) | Agonistas etilamino amino sustituidos del receptor beta 2 adrenergico | |
| CO6231027A2 (es) | Metodos e intermediarios para preparar compuestos de lactama lactoma de 8 atomos de carbono activos como inhibidores de renina | |
| AR077534A1 (es) | Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5 | |
| AR078155A1 (es) | Derivados de benzodiazepinas, composiciones farmaceuticas y sus usos | |
| AR054790A1 (es) | Metodos para el tratamiento de disfuncion sexual | |
| CO5700747A2 (es) | Piperidinas novedosas como moduladores de quimoquina (ccr) | |
| AR072880A1 (es) | Derivados nitrogenados de la pancratistatina | |
| AR054102A1 (es) | Derivados de fenil-piperazina-metanona. procesos de obtencion y composiciones farmaceuticas | |
| AR083492A1 (es) | Derivados aminicos para el tratamiento de trastornos proliferativos de la piel | |
| PE20090851A1 (es) | Derivados de piperidina como moduladores de los receptores de quimoquinas |